Protagonist Therapeutics Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Friday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 12 2025
0mins
Should l Buy SARO?
Source: Benzinga
Analyst Ratings Updates: Top Wall Street analysts have revised their outlooks on several companies, including Theravance Biopharma, Protagonist Therapeutics, and StandardAero, with new ratings and price targets announced.
Specific Stock Ratings: B. Riley Securities rated Theravance Biopharma with a Buy and a target of $28; Protagonist Therapeutics received an Outperform rating with a target of $73; and Barclays rated StandardAero as Overweight with a target of $32.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SARO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SARO
Wall Street analysts forecast SARO stock price to rise
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 30.020
Low
30.00
Averages
35.00
High
39.00
Current: 30.020
Low
30.00
Averages
35.00
High
39.00
About SARO
StandardAero, Inc. is an independent, pure-play provider of aerospace engine aftermarket services for fixed and rotary wing aircraft, serving the commercial, military and business aviation end markets. The Company provides a comprehensive suite of critical, value-added aftermarket solutions, including engine maintenance, repair and overhaul, engine component repair, on-wing and field service support, asset management and engineering solutions. The Company's segments include Engine Services and Component Repair Services. The Engine Services segment provides engine and airframe maintenance, repair, overhaul and related services to customers in the commercial aerospace, military & helicopter, and business aviation end markets. The Component Repair Services segment supports the commercial aerospace, military and helicopter and other end markets, including marine and land, and oil and gas with engine piece part repair, accessory repair and engine new part manufacturing.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Earnings Release Schedule: StandardAero will report its Q4 and full year 2025 earnings after market close on February 25, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Timing: The company will hold a conference call at 5:00 PM ET on the same day to discuss the earnings results, enhancing communication with investors.
- Live Webcast Availability: The earnings release and conference call will be available via live webcast on StandardAero's investor relations website, ensuring global investors can access real-time information.
- Replay Service: For investors unable to attend the live call, StandardAero offers a replay service available until March 11, 2026, ensuring widespread dissemination of information.
See More
- Earnings Release Schedule: StandardAero will release its Q4 and full year 2025 earnings after market close on February 25, 2026, providing insights into the company's annual performance and future outlook.
- Conference Call Details: The company will hold a conference call at 5:00 PM ET on the same day to discuss the earnings report, allowing investors to dial in at (877) 407-9762 or (201) 689-8538, ensuring transparency of information.
- Live Webcast Availability: The earnings release and conference call will be available via live webcast on StandardAero's investor relations website, enabling global investors to access real-time information and enhancing corporate transparency.
- Replay Service: For those unable to attend the live call, StandardAero offers a replay service available until March 11, 2026, at 11:59 PM ET, ensuring all investors can access critical information.
See More
- Disappointing Earnings: Qorvo reported third-quarter financial results with fourth-quarter revenue guidance projected between $775 million and $825 million, significantly below the market estimate of $904.59 million, indicating sales pressure on the company.
- Lowered Earnings Expectations: The company anticipates adjusted earnings per share in the range of $1.05 to $1.35 for the fourth quarter, compared to the market expectation of $1.37, reflecting potential declines in profitability.
- Significant Stock Reaction: In pre-market trading, Qorvo shares fell 10.5% to $74.11, as investor concerns over the financial outlook weakened market confidence.
- Market Trend Divergence: While Nasdaq 100 futures rose over 200 points, Qorvo's negative earnings report impacted its stock price, highlighting a divergence between individual stock performance and overall market trends.
See More
- Earnings Beat: F5, Inc. reported Q1 earnings of $4.45 per share, exceeding analyst expectations of $3.65 by 21.88%, indicating a significant improvement in profitability that is likely to positively impact stock prices.
- Revenue Growth: The quarterly revenue reached $822.47 million, surpassing the Street estimate of $758.08 million, demonstrating enhanced competitiveness in the market that may attract more investor interest.
- Optimistic Outlook: The company provided second-quarter sales guidance above estimates and raised its FY26 guidance, reflecting management's confidence in future growth, which could further drive stock price increases.
- Positive Stock Reaction: F5 shares jumped 10.9% to $299.99 in pre-market trading, indicating strong market response to its earnings report, which may draw in more investors and bolster market confidence.
See More
- Public Offering Pricing: StandardAero announced the pricing of 50 million shares of common stock at $31.00 per share, expected to close on January 29, 2026, which will provide liquidity for shareholders and may impact the company's stock price.
- Shareholder Proceeds: All net proceeds from the offering will go to the selling stockholders, indicating that the company is not directly raising funds but providing an exit opportunity for shareholders, which could affect market perceptions of the company's future financing capabilities.
- Stock Repurchase Plan: Concurrently, the company has entered into an agreement to repurchase $50 million of its common stock at the same price as the public offering, aimed at enhancing earnings per share and boosting shareholder confidence.
- Underwriter Lineup: A consortium of prominent investment banks, including Morgan Stanley and J.P. Morgan, is acting as joint lead book-running managers for the offering, reflecting strong market confidence in StandardAero and its leadership position in the aerospace aftermarket.
See More
- Public Offering Announcement: StandardAero disclosed that its stockholders plan to sell 50 million shares in an underwritten public offering, which is expected to enhance liquidity but will not provide any proceeds to the company, potentially impacting its capital structure.
- Additional Share Option: The selling stockholders are expected to grant underwriters a 30-day option to purchase an additional 7.5 million shares, a strategy that may dilute existing shareholders' stakes and increase market uncertainty.
- Stock Repurchase Agreement: Concurrently, StandardAero announced a $50 million repurchase of common stock from a selling stockholder, aimed at boosting shareholder confidence and stabilizing the stock price, contingent on the completion of the offering.
- Market Reaction: Following the announcement, StandardAero's stock fell 3.95% in after-hours trading to $31.81, reflecting market caution regarding the implications of the offering and repurchase plan.
See More








